Awardee OrganizationUNIVERSITY OF CALIFORNIA, SAN FRANCISCO
Description
Abstract Text
DESCRIPTION (Adapted from the applicant's abstract): Acting through
humoral and/or autocrine/paracrine mechanisms, the insulin-like growth
factors stimulate the differentiation of muscle cells. Whereas both IGF-I
and IGF-II stimulate myogenesis, IGF-II is the principle IGF peptide
expressed by muscle cells and is, therefore, likely to play a more
fundamental role in the differentiation process.Studies in this proposal
will test the hypothesis that IGF-II stimulates muscle cell differentiation
by increasing the expression and action of myogenin, a differentiation
master control gene for skeletal muscle.In addition, studies will test the
hypothesis that the effects of IGF-II on myogenin expression are mediated
through the IGF-I receptor and that IGF-binding proteins modulate the
effects of IGF on myogenin expression and skeletal muscle differentiation.
To test these hypotheses, studies will address the following specific aims:
(1) To examine the effects of IGF-II on the mRNA abundance, transcription,
protein biosynthesis, and binding of myogenin onto DNA regulatory elements,
and on the expression of the transcription factors, E12 and Id, the
principal peptides with which myogenin dimerizes; (2) to examine which IGF-
receptor subtypes mediate the effects of IGF-II on the expression of
myogenin and E12 and Id, using recently defined IGF-II analogs that have
selective affinity for the IGF-II receptor in binding, cross-linking, and
mRNA abundance studies; and (3) to explore the potential role of IGF-
binding proteins and IGF-induced myogenin gene expression with an IGF
analog with reduced affinity for binding proteins but unaltered affinity
for IGF receptors.
National Institute of Diabetes and Digestive and Kidney Diseases
CFDA Code
DUNS Number
094878337
UEI
KMH5K9V7S518
Project Start Date
01-May-1992
Project End Date
30-April-1997
Budget Start Date
01-May-1994
Budget End Date
30-April-1995
Project Funding Information for 1994
Total Funding
$100,100
Direct Costs
$70,000
Indirect Costs
$30,100
Year
Funding IC
FY Total Cost by IC
1994
National Institute of Diabetes and Digestive and Kidney Diseases
$100,100
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 5R29DK044181-03
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 5R29DK044181-03
Patents
No Patents information available for 5R29DK044181-03
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 5R29DK044181-03
Clinical Studies
No Clinical Studies information available for 5R29DK044181-03
News and More
Related News Releases
No news release information available for 5R29DK044181-03
History
No Historical information available for 5R29DK044181-03
Similar Projects
No Similar Projects information available for 5R29DK044181-03